Acadia Pharmaceuticals presents interim data from LOTUS study

Acadia Pharmaceuticals announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation, IRSF, Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE. “These interim data from the LOTUS study reinforce that the clinical effectiveness of DAYBUE in the real-world setting is consistent with results observed in the DAYBUE Phase 3 clinical trial program and further characterize what Rett syndrome symptom improvements may look like to caregivers,” said Ponni Subbiah, M.D., M.P.H., Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. “These initial findings also illustrate caregivers’ strategies to manage gastrointestinal tolerability in the real world and underscore the value of education and effective implementation of diarrhea management strategies to help families improve the patient experience.”